A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Amgen Inc stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 65,075 shares of AMGN stock, worth $20.9 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
65,075
Previous 65,978 1.37%
Holding current value
$20.9 Million
Previous $20.6 Million 1.71%
% of portfolio
0.19%
Previous 0.2%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$309.38 - $337.38 $279,370 - $304,654
-903 Reduced 1.37%
65,075 $21 Million
Q2 2024

Jul 17, 2024

SELL
$262.75 - $319.31 $746,735 - $907,479
-2,842 Reduced 4.13%
65,978 $20.6 Million
Q1 2024

Apr 23, 2024

SELL
$268.87 - $324.56 $547,419 - $660,804
-2,036 Reduced 2.87%
68,820 $19.6 Million
Q4 2023

Feb 01, 2024

SELL
$255.7 - $288.46 $233,198 - $263,075
-912 Reduced 1.27%
70,856 $20.4 Million
Q3 2023

Nov 03, 2023

BUY
$218.65 - $271.46 $127,472 - $158,261
583 Added 0.82%
71,768 $19.3 Million
Q2 2023

Aug 01, 2023

SELL
$214.27 - $253.37 $1.79 Million - $2.12 Million
-8,374 Reduced 10.53%
71,185 $15.8 Million
Q1 2023

May 02, 2023

SELL
$225.79 - $275.2 $1.08 Million - $1.32 Million
-4,804 Reduced 5.69%
79,559 $19.2 Million
Q4 2022

Mar 02, 2023

SELL
$229.03 - $291.01 $23,132 - $29,392
-101 Reduced 0.12%
84,363 $22.2 Million
Q4 2022

Feb 14, 2023

SELL
$229.03 - $291.01 $1.84 Million - $2.34 Million
-8,051 Reduced 8.7%
84,464 $22 Million
Q3 2022

Oct 25, 2022

SELL
$224.46 - $253.15 $46,238 - $52,148
-206 Reduced 0.22%
92,515 $20.9 Million
Q2 2022

Jul 26, 2022

SELL
$230.71 - $256.74 $533,170 - $593,326
-2,311 Reduced 2.43%
92,721 $22.6 Million
Q1 2022

Apr 13, 2022

BUY
$219.27 - $242.57 $483,490 - $534,866
2,205 Added 2.38%
95,032 $23 Million
Q4 2021

Feb 14, 2022

BUY
$198.88 - $227.6 $322,782 - $369,394
1,623 Added 1.78%
92,827 $20.9 Million
Q3 2021

Nov 12, 2021

BUY
$212.27 - $248.7 $845,471 - $990,572
3,983 Added 4.57%
91,204 $19.4 Million
Q2 2021

Aug 13, 2021

BUY
$233.58 - $259.14 $679,250 - $753,579
2,908 Added 3.45%
87,221 $21.3 Million
Q1 2021

Apr 14, 2021

BUY
$221.91 - $258.6 $929,137 - $1.08 Million
4,187 Added 5.23%
84,313 $21 Million
Q4 2020

Jan 14, 2021

SELL
$216.38 - $257.67 $17,094 - $20,355
-79 Reduced 0.1%
80,126 $18.4 Million
Q3 2020

Oct 15, 2020

SELL
$234.65 - $260.95 $348,455 - $387,510
-1,485 Reduced 1.82%
80,205 $20.4 Million
Q2 2020

Jul 30, 2020

SELL
$197.81 - $242.74 $52,815 - $64,811
-267 Reduced 0.33%
81,690 $19.3 Million
Q1 2020

Apr 15, 2020

SELL
$182.24 - $241.7 $1.11 Million - $1.47 Million
-6,070 Reduced 6.9%
81,957 $16.6 Million
Q4 2019

Jan 22, 2020

BUY
$189.21 - $243.2 $1.88 Million - $2.42 Million
9,947 Added 12.74%
88,027 $21.2 Million
Q3 2019

Nov 05, 2019

SELL
$174.11 - $208.62 $1.99 Million - $2.38 Million
-11,421 Reduced 12.76%
78,080 $15.1 Million
Q2 2019

Aug 09, 2019

SELL
$166.7 - $195.41 $509,601 - $597,368
-3,057 Reduced 3.3%
89,501 $16.5 Million
Q1 2019

Apr 08, 2019

SELL
$180.87 - $203.88 $835,981 - $942,333
-4,622 Reduced 4.76%
92,558 $17.6 Million
Q4 2018

Feb 13, 2019

SELL
$178.4 - $208.25 $40,318 - $47,064
-226 Reduced 0.23%
97,180 $18.9 Million
Q3 2018

Oct 31, 2018

SELL
$185.29 - $208.89 $18,714 - $21,097
-101 Reduced 0.1%
97,406 $20.2 Million
Q2 2018

Aug 07, 2018

SELL
$166.05 - $186.51 $136,991 - $153,870
-825 Reduced 0.84%
97,507 $18 Million
Q1 2018

Apr 20, 2018

BUY
$169.43 - $198.0 $343,434 - $401,346
2,027 Added 2.1%
98,332 $16.8 Million
Q4 2017

Feb 08, 2018

BUY
$168.79 - $188.59 $919,905 - $1.03 Million
5,450 Added 6.0%
96,305 $16.7 Million
Q3 2017

Oct 27, 2017

BUY
$167.29 - $191.0 $774,050 - $883,757
4,627 Added 5.37%
90,855 $16.9 Million
Q2 2017

Aug 07, 2017

BUY
N/A
86,228
86,228 $0

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $172B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Loring Wolcott & Coolidge Fiduciary Advisors LLP Portfolio

Follow Loring Wolcott & Coolidge Fiduciary Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.